Trials / Completed
CompletedNCT00128544
Telbivudine Versus the Combination of Telbivudine and Valtorcitabine in Patients With Chronic Hepatitis B
A Randomized, Blinded, Phase IIb Trial of Telbivudine (LdT) Versus the Combination of Telbivudine and Valtorcitabine (Val-LdC) in Patients With Chronic Hepatitis B
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 130 (planned)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- —
Summary
This study is being conducted to compare the effectiveness of the combination of valtorcitabine and telbivudine to telbivudine alone in patients with chronic hepatitis B.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | telbivudine | |
| DRUG | valtorcitabine |
Timeline
- Start date
- 2005-05-01
- Primary completion
- 2007-05-01
- Completion
- 2007-05-01
- First posted
- 2005-08-10
- Last updated
- 2017-06-16
Locations
3 sites across 3 countries: Hong Kong, New Zealand, Singapore
Source: ClinicalTrials.gov record NCT00128544. Inclusion in this directory is not an endorsement.